AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01204281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation mode (PAV+ vs. ACV)
Description: Compare two ventilatory modes in the acute phase of illness
Study NCT01204281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation mode (PAV+ vs. ACV)
Description: Compare two ventilatory modes in the acute phase of illness
Study NCT03178890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OHMG
Description: Device will be implanted in all enrolled patients.
Study NCT04355689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-001
Description: oral tablet
Study NCT04355689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT02615496 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
Study NCT02615496 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD.
Study NCT02917538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Both groups will receive radiofrequency ablation treatment
Study NCT02917538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Both groups will receive radiofrequency ablation treatment
Study NCT02396888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the wound surface was treated daily with 0.1 cc of normal saline.
Study NCT00004163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT03876808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger™ Temperature Management Unit Model 750
Description: Forced-air temperature management unit used for preoperative and intraoperative participant warming
Study NCT03876808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Bair Paws™ Flex Gown
Description: Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
Study NCT04009135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet delivered cognitive behavioural therapy (iCBT)
Description: The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
Study NCT04009135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online delivered acceptance and commitment therapy (iACT)
Description: The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
Study NCT04009135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AC)
Description: 1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
Study NCT03958604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurostimulation
Description: Spinal cord stimulation with burst modality for discogenic low back pain
Study NCT00100750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00100750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT00100750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT06472570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy boost
Description: A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy
Study NCT02015832 — intervention group
Intervention type: DEVICE
Intervention: Coronary stent
Study NCT02015832 — intervention group
Intervention type: RADIATION
Intervention: Multi Slice Computed Tomography
Description: A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
Study NCT02015832 — intervention group
Intervention type: DEVICE
Intervention: instantaneous wave-free ratio
Description: Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
Study NCT02015832 — intervention group
Intervention type: DEVICE
Intervention: Fractional flow reserve
Description: Pressure-derived index on physiological assessment of stenosis severity
Study NCT02015832 — intervention group
Intervention type: DEVICE
Intervention: Intravascular Ultrasound
Description: Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
Study NCT00550147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oros Methylphenidate
Description: Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM.
Study NCT00550147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule.
Study NCT03209115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of calcium hydroxide and chlorhexidine
Description: placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
Study NCT03209115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
Study NCT01214980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
Study NCT01214980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care provided per site-specific protocol
Study NCT01074827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training and treadmill training
Description: Eight weeks of intensive strength training or treadmill training
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo, same number of doses as active comparator in that arm
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg
Description: Inhaled Staccato Fentanyl, 25 mcg x 1 dose
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl 25 mcg
Description: Intravenous Fentanyl 25 mcg, single dose
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 2
Description: Inhaled Staccato Fentanyl, 25 mcg x 2 doses
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 4
Description: Inhaled Staccato Fentanyl, 25 mcg x 4 doses
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 6
Description: Inhaled Staccato Fentanyl, 25 mcg x 6 doses
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04090398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT04090398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04090398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04090398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04090398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT04090398 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT02545530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal clonidine
Description: 2.5mg/patch per week
Study NCT02439411 — intervention group
Intervention type: DRUG
Intervention: Trametinib
Study NCT00402350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 12
Description: Inhaled Staccato Fentanyl, 25 mcg x 12 doses
Study NCT01097616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant High Dose (HD)
Description: Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT01097616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Low Dose (LD)
Description: Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT01097616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study NCT00915811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
Study NCT00915811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulphan
Description: Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
Study NCT00915811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
Description: Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
Study NCT00915811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell infusion
Description: The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
Study NCT02952547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156
Study NCT02952547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1366 Tab.
Study NCT04170075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Undergo WBV
Study NCT02572687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT04164212 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flumist Quadrivalent Nasal Product
Description: FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Study NCT03396393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study NCT02365857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine & Bupivacaine.
Description: Intrathecal injection of Dexmedetomidine \& Bupivacaine.
Study NCT02365857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Only.
Description: Intrathecal injection of Bupivacaine only.
Study NCT00674167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
Study NCT03021525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Goal Directed Therapy
Description: The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
Study NCT03021525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure >65 mmHg, SpO2>94%, and core temperature >36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
Study NCT02572687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Administered IV
Study NCT00674167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
Study NCT01003587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: District health information package
Description: The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages
Study NCT01342640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paroxetine IR 10mg tablet
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paroxetine IR 20mg tablet
Description: 1 tablet once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day
Study NCT04046094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid Intravenous
Study NCT00674167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
Study NCT04542538 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Study NCT03031795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral Tablet
Study NCT03031795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine IR 10mg or 20mg
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5mg tablet
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25mg tablet
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day
Study NCT00866294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine CR 12.5mg or 25mg
Description: 1 or 2 tablets once a day
Study NCT02935881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio Frequency Ablation (RFA) (Stretta Procedure)
Description: Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
Study NCT02935881 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.